Juliusson, Gunnar

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology

Cancer-related Molecular PathwaysAcute Myeloid Leukemia Research

Cited by 406

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia

Anguille, S., Van de Velde, A. L., Smits, E. L., Van Tendeloo, V. F., Juliusson, G., Cools, N., Nijs, G., Stein, B., Lion, E., Van Driessche, A., et al. (2017) · Blood

Immunotherapy and Immune ResponsesAcute Myeloid Leukemia Research

Cited by 230

Selective killing of candidate AML stem cells by antibody targeting of IL1RAP

Askmyr, M., Ågerstam, H., Hansen, N., Gordon, S., Arvanitakis, A., Rissler, M., Juliusson, G., Richter, J., Järås, M., & Fioretos, T. (2013) · Blood

Acute Myeloid Leukemia ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 127

An open-label phase I dose-finding study of APR-246 in hematological malignancies

Deneberg, S., Cherif, H., Lazarevic, V, Andersson, P.-O., von Euler, M., Juliusson, G., & Lehmann, S. (2016) · Blood Cancer Journal

Cancer-related Molecular PathwaysAcute Myeloid Leukemia Research

Cited by 84